Cytori
Therapeutics, Inc. (NASDAQ: CYTX) announced today that data from
preclinical studies showing potential for Cytori’s DCCT-10 cell therapy
product in the treatment of hypertrophic scarring (HTS), a common
consequence of burn injury, will be presented at the Annual Meeting of
the American Burn Association (ABA) in Las Vegas on May 5, 2016.
This research is a continuation of Cytori’s ongoing contract with the
Biomedical Advanced Research and Development Authority (BARDA). As part
of this work Cytori has developed a reproducible model possessing
several of the characteristics of the HTS that occurs in humans
following burn injury. In one study this model was applied to assess the
ability of DCCT-10 treatment delivered immediately following initial
burn surgery to impact the development of HTS. In a second study the
same model was applied to assess use of DCCT-10 delivered six months
after deep partial thickness injury in which a hypertrophic scar had
already formed. The Cytori presentation will include early data
indicating a potential beneficial effect of DCCT-10 in both processes.
This research is an extension of earlier work that reported data
suggesting that use of DCCT-10 was associated with improvement in
several parameters associated with healing following thermal burn injury.
Hypertrophic scars are areas of hard, raised, red or purple scar tissue
that often form at the site of burn injury. They are frequently
hypersensitive and itchy. When present at or near a joint they can form
contractures that reduce range of motion. In the absence of adequate
non-surgical treatment options, the most effective approach has been to
attempt to prevent or limit the formation of these scars by
post-surgical use of pressure garments, steroid injections, and silicone
sheets. Surgical intervention is often used to release contracture.
About Cytori
Cytori Therapeutics is a late stage cell therapy company developing
autologous cell therapies from adipose tissue to treat a variety of
medical conditions. Data from preclinical studies and clinical trials
suggest that Cytori Cell Therapy™ acts principally by improving blood
flow, modulating the immune system, and facilitating wound repair. As a
result, Cytori Cell Therapy™ may provide benefit across multiple disease
states and can be made available to the physician and patient at the
point-of-care through Cytori’s proprietary technologies and products.
For more information: visit www.cytori.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release includes forward-looking statements that involve
known and unknown risks and uncertainties. All statements, other than
historical facts are forward looking statements. Such statements are
subject to risks and uncertainties that could cause our actual results
and financial position to differ materially. Some of these risks include
pre-clinical and clinical associated with the BARDA wound trial
(including risks in the collection and results of clinical data), and
other risks and uncertainties described under the "Risk Factors" in
Cytori’s Securities and Exchange Commission Filings, included in our
annual and quarterly reports.
There may be events in the future that we are unable to predict, or over
which we have no control, and our business, financial condition, results
of operations and prospects may change in the future. We assume no
responsibility to update or revise any forward- looking statements to
reflect events, trends or circumstances after the date they are made
unless we have an obligation under U.S. Federal securities.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160414005473/en/
Copyright Business Wire 2016